Viral vector vaccines to treat colorectal cancer

N. Ashraf, Amit Mahipal, Richard Kim

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Despite recent advances in the diagnosis and treatment of colorectal cancer, it remains the second commonest cause of cancer deaths in the USA. Current therapeutic agents have provided a small, incremental survival benefit at the cost of significantly increased toxicities. There is a huge unmet need for novel effective therapies. Colorectal cancer evades the host immune surveillance as a result of weak immunogenicity and immunosuppressive effects of cancer cells. Cancer vaccines have the potential to activate the immune system against colorectal cancer cells by increasing the expression and presentation of tumor-associated antigens. Recent clinical trials using viral-vector-based cancer vaccines have demonstrated clinical benefit with excellent safety profiles in patients with metastatic colorectal cancer. Here, we review the rationale for immunotherapy in colon cancer; clinical trial data for viral-vector-based colorectal cancer vaccines, the advantages and disadvantages of viral vectors, and future treatment strategies.

Original languageEnglish (US)
Pages (from-to)398-405
Number of pages8
JournalCurrent Colorectal Cancer Reports
Issue number4
StatePublished - Dec 2013


  • Colon cancer
  • Colon cancer immunogenicity
  • Immunotherapy
  • Review
  • Vaccine
  • Viral vaccines

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology


Dive into the research topics of 'Viral vector vaccines to treat colorectal cancer'. Together they form a unique fingerprint.

Cite this